title: Future directions for antifolate drug development.
abstract: We have discussed potential ways by which new antifolates could be designed and utilized to effect both sensitive and resistant cell/tumor inhibition. Targeting of alternative folate-dependent enzymes and increasing net intracellular accumulation (transport) and polyglutamation of antifolates should be useful approaches. In addition, antibodies to and cloned cDNAs of the transport components (e.g., folate transport proteins) will allow better characterization and understanding of de novo and acquired antifolate resistance states and may provide insights into new drug development.
authors.affiliation: Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland 20892.
authors.forename: C B
authors.initials: CB
authors.lastname: Knight
authors.forename: P C
authors.initials: PC
authors.lastname: Elwood
authors.forename: B A
authors.initials: BA
authors.lastname: Chabner
mesh_terms: D000818:Animals; D001692:Biological Transport; D015195:Drug Design; D005492:Folic Acid / Q000378:metabolism; D005493:Folic Acid Antagonists / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D014407:Tumor Cells, Cultured
chemical_list: D005493:Folic Acid Antagonists; D005492:Folic Acid